Unique ID issued by UMIN | UMIN000040487 |
---|---|
Receipt number | R000046212 |
Scientific Title | Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus |
Date of disclosure of the study information | 2020/05/22 |
Last modified on | 2020/11/27 17:31:22 |
Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus
Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus
Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus
Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitus
Japan |
type 1 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
To clarify patient satisfaction in using SGLT2 inhibitors in patients with type 1 diabetes
Safety,Efficacy
Changes of Satisfaction score measured in the DTSQ by five possible responses (varying from -2; very dissatisfied, to +2; very satisfied, varying by integers), both previous and three months subsequent to ipragliflozin administration.
To assess safety and efficacy, the data prior to and three months subsequent of the oral administration of the SGLT2 inhibitor were collected such as body mass index, body composition, glycated hemoglobin (HbA1c), and glycemic variability were obtained from flash glucose monitoring (FGM) systems (Free Style Libre; Abbott Diabetes Care, Witney, UK) measured for three months prior to and three months subsequent of the oral administration of the SGLT2 inhibitor. Retrospective data included the insulin dose, the number of severe hypoglycemia incidence requiring assistance, diabetic ketoacidosis, and other side effects.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
50mg of ipragliflozin
20 | years-old | <= |
80 | years-old | >= |
Male and Female
Type 1 diabetes mellitus obtained consent to participate in research
Patients with glycated hemoglobin (HbA1c) of 6.5% or higher and less than 10%
Patients with body mass index (BMI) of 18.5 kg/m2 or higher
Patients who do not agree to participate in the study
Patients judged by the attending physician that there is no indication for SGLT2 inhibitor administration
25
1st name | Ryoichi |
Middle name | |
Last name | Ishibashi |
Kimitsu Chuo Hospital
Department of Medicine, Division of Diabetes, Endocrinology and Metabolism
292-8535
1010 Sakurai, Kisarazu-city, Chiba
+81-438-36-1071
ishibashi-cib@umin.net
1st name | Ryoichi |
Middle name | |
Last name | Ishibashi |
Kimitsu Chuo Hospital
Department of Medicine, Division of Diabetes, Endocrinology and Metabolism
292-8535
1010 Sakurai, Kisarazu-city, Chiba
+81-438-36-1071
ishibashi-cib@umin.net
Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital
none
Self funding
Kimitsu Chuo Hospital
1010 Sakurai, Kisarazu-city, Chiba
+81-438-36-1071
soumu@kc-hosp.or.jp
NO
2020 | Year | 05 | Month | 22 | Day |
http://link.springer.com/article/10.1007/s13300-020-00971-2
Partially published
http://link.springer.com/article/10.1007/s13300-020-00971-2
24
Completed
2019 | Year | 03 | Month | 26 | Day |
2019 | Year | 03 | Month | 26 | Day |
2019 | Year | 03 | Month | 26 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 11 | Month | 12 | Day |
2020 | Year | 11 | Month | 12 | Day |
2020 | Year | 11 | Month | 12 | Day |
http://link.springer.com/article/10.1007/s13300-020-00971-2
2020 | Year | 05 | Month | 22 | Day |
2020 | Year | 11 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046212
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |